Richard Fine, MD
Surgical Oncology · Memphis, TNNPI 1295702934
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.9%. Reporting peaked in 2021 at $2,812 and has fallen 76.3% since, to $666 in 2025.
Across 61 payments — averaging $135.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hologic Inc$2K
- Endomagnetics Ltd$1K
- Merit Medical Systems Inc$1K
- Puma Biotechnology, Inc.$1K
- AstraZeneca$806
- Myriad Genetic Laboratories, Inc.$748
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,38129%
- Travel & lodging$1,13214%
- Food & beverage$4,53955%
- Education$2103%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hologic Inc | 12 | $1,977 |
| Endomagnetics Ltd | 8 | $1,089 |
| Merit Medical Systems Inc | 12 | $1,078 |
| Puma Biotechnology, Inc. | 1 | $1,000 |
| AstraZeneca | 1 | $806 |
| Myriad Genetic Laboratories, Inc. | 4 | $748 |
| Elucent Medical | 1 | $543 |
| Leica Microsystems Inc. | 1 | $210 |
| Molli Surgical (US) Inc | 1 | $197 |
| Dilon Technologies, Inc. | 1 | $106 |
| Galvanize Therapeutics, Inc | 1 | $105 |
| Innovation Technologies Inc | 2 | $88 |
| Bioptics, Inc. | 2 | $80 |
| Merck | 3 | $48 |
| Cardinal Health 414 LLC | 2 | $39 |
| Bard Peripheral Vascular, Inc. | 3 | $36 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Stryker | 1 | $26 |
| Boston Scientific | 1 | $19 |
| Avanos Medical | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| Nalu Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nerlynx$1,000
- Magseed$955
- Magtrace$955
- Savi SCOUT$880
- LYNPARZA$806
- myRisk$703
- BioZorb$497
- MAMMOPAD RADIOLUCENT CUSHION$247
- MAMMOSITE$191
- Localizer$158
- AIXPLORER ULTIMATE$114
- HemoBlast Bellows$106
- ALIYA SYSTEM$105
How this compares
$8,261 in reported general payments places this provider in the 80th percentile of 53 surgical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 15 | $171 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Memphis
- Richard GilmoreMemphis$3K
- Miriam TsaoMemphis$2K
- Ashley HendrixMemphis$2K
- Shuja AhmedMemphis$2K
- Keli TurnerMemphis$2K
- Ian SolskyMemphis$2K
- David ShibataMemphis$1K
- Nicholas EconomidesMemphis$599
- Chelsea OlsonMemphis$398
- Christine MrozMemphis$136
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.